Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy

Keyphrases

• Orally Bioavailable 100%
• STAT3 Inhibitor 100%
• Cancer Therapy 100%
• Fragment Based Drug Design 100%
• Drug Identification 100%
• Pancreatic Cancer Cells 33%
• Cell Cycle Progression 33%
• Promoter Activity 33%
• Human Cancer 33%
• Drug Candidates 33%
• Phosphorylation 33%
• Pharmacological Evaluation 33%
• Chemical Synthesis 33%
• Synthetic Evaluation 33%
• Drug-like 33%
• IC50 Value 33%
• Cleaved caspase-3 33%
• Therapeutic Target 33%
• Tumor Growth in Vivo 33%
• Anticancer Agents 33%
• Breast Cancer Cells 33%
• Enhanced Activity 33%
• Promote Apoptosis 33%
• MDA-MB-231 33%
• Xenograft Tumor Growth 33%
• Estrogen Receptor-positive Breast Cancer 33%
• Lead Molecules 33%
• Novel Scaffolds 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Malignant Neoplasm 100%
• Drug Development 100%
• Pancreas Cancer 33%
• Tumor Growth 33%
• Breast Cancer 33%
• Anticarcinogen 33%
• Caspase 3 33%
• IC50 33%
• Estrogen Receptor Negative Breast Cancer 33%